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Chengdu, China, 3 Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell
University, Ithaca, NY, USA
Six in vivo-induced (IVI) antigens—RnhB, GalU, GalT, Apl_1061, Apl_1166, and HflX
were selected for a vaccine trial in a mouse model. The results showed that the
IgG levels in each immune group was significantly higher than that of the negative
control (P < 0.001). Except rRnhB group, proliferation of splenocytes was observed
in all immunized groups and a relatively higher proliferation activity was observed in
rGalU and rGalT groups (P < 0.05). In the rGalT vaccinated group, the proportion of
CD4+ T cells in spleen was significant higher than that of negative control (P < 0.05).
Moreover, proportions of CD4+ T cells in other vaccinated groups were all up-regulated
to varying degrees. Up-regulation of both Th1 (IFN-γ, IL-2) and Th2 (IL-4) cytokines
were detected. A survival rate of 87.5, 62.5, and 62.5% were obtained among rGalT,
rAPL_1166, and rHflX group, respectively while the remaining three groups was only
25%. Histopathological analyses of lungs indicated that surviving animals from the
vaccinated groups showed relatively normal pulmonary structure alveoli. These findings
confirm that IVI antigens used as vaccine candidates provide partial protection against
Actinobacillus pleuropneumoniae infection in a mouse model, which could be used as
potential vaccine candidates in piglets.
Keywords: Actinobacillus pleuropneumoniae, IVI antigens, putative vaccine candidates, humoral immune
response, cellular immune response
INTRODUCTION
Actinobacillus pleuropneumoniae (APP) was first isolated from pig lung in 1957 and initially
described as Haemophilus-like organism, and is one of the most important respiratory pathogens
in pigs (Matthews and Pattison, 1961; Fraile et al., 2010). This pathogen causes porcine contagious
pleuropneumoniae (PCP), which is a major problem for the pig industry worldwide (Fraile et al.,
2010; Jirawattanapong et al., 2010; Fablet et al., 2012; Merialdi et al., 2012; Hillen et al., 2014). To
date, 15 different serotypes have been identified and the dominant serotypes are different in the
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various APP endemic regions of the world (Mittal et al., 1983;
Klein et al., 2003; Kaplan and Mulks, 2005; Bosse et al., 2014).
Control of PCP is still a difficult problem worldwide.
This disease has long been the subject of numerous studies
encompassing many areas like diagnosis, pathogenesis,
vaccination, etc. (Jacobsen et al., 2005; Oldfield et al., 2009;
Costa et al., 2011; Wei et al., 2012; Lopez-Bermudez et al.,
2014; Tobias et al., 2014). Furthermore, studies have found
an increasing resistance against antimicrobial agents used in
pig pleuropneumonia therapy (Aarestrup and Jensen, 1999;
Archambault et al., 2012; Vanni et al., 2012). Routine use of
antibiotics in livestock to boost animal growth has inadvertently
selected for pathogen resistance; this is thought to be the primary
factor behind the rapid increase of resistant APP strain outbreaks
observed on pig farms worldwide. This issue has received an
increasing amount of attention in developed countries, as well as
developing ones such as China.
Commercial inactivated vaccines against APP are used
routinely in the porcine agronomy. Moreover, a number of
recombinant antigens of APP were demonstrated to be putative
vaccine candidates. Most of the current commercial vaccines
against this pathogen are traditional inactivated bacterins, which
elicit only partial protection, with decreased mortality but not
morbidity rates (Lu et al., 2011). Traditionally, inactivated
vaccines are developed using one or more serovars, which is
(are) selected from the local prevalent strain(s). Often, there are
multiple serovars prevalent in one country or district (Mittal
et al., 1983; Angen et al., 2008; Hälli et al., 2014; Marois-Crehan
et al., 2014; Gottschalk and Lacouture, 2015). Because of a lack
of cross-protection between different serovars, it is difficult to
control PCP effectively using inactivated bacterins (Rycroft and
Garside, 2000). APP virulence factors such as apx toxins, are
selected as vaccine candidates and show partial cross-protection
among different serovars, which are conserved in APP strains
(Wang et al., 2009; Seo et al., 2013). In addition, other virulent
factors like AasP autotransporter protein (Oldfield et al., 2009),
pilin (Lu et al., 2011) were also studied for their potential as
vaccine candidates. A number of in vivo-induced (IVI) antigens
are up-regulated after infection in vivo, which are essential for
pathogenesis and survival in host internal environment (Salim
et al., 2005). Recently, advances in biotechnology have allowed
for the development of techniques such as IVI antigen technology
(IVIAT; Handfield et al., 2000), signature-tagged mutagenesis
(STM; Fuller et al., 2000), and selective capture of transcribed
sequences (SCOTS; Baltes et al., 2007). These techniques were
proven to be effective in the study of virulence factors.
A number of IVI antigens were identified in our previous
studies (Zhang et al., 2015). To evaluate the potential of IVI
antigens as vaccine candidates, six antigens were randomly
selected from a list of previously identified IVI antigens. In
our previous study, IVIAT was used to screen in vivo up-
regulation antigens of APP; a number of antigens were identified
which were involved in metabolism, replication, transcription
regulation, signal transduction, and several function-unknown
proteins (Zhang et al., 2015). Six of these were expressed as His-
tagged fusion proteins and screened for their potential as vaccine
candidates against App in a murine model.
MATERIALS AND METHODS
Animals and Ethics Statement
Six to eight week female BALB/c mice (18–22 g) were purchased
from Chengdu Dossy Experimental Animal Co., Ltd. The
animal experiments were conducted in compliance with the
animal protocol approved by the Veterinary Medical College at
Sichuan Agricultural University. All procedures performed in
this study involving animals were approved by the Institutional
Animal Care and Use Committee of Sichuan Agricultural
University (Approval Number BK2014-047), Sichuan, China
and followed the guidelines of the National Institutes of
Health.
Bacterial Strains, Media, and Culture
Conditions
Recombinant constructs were made using gene recombination
technology. E. coli DH5α (TIANGEN, China) was used for
cloning of recombinants and E. coli BL21 (TIANGEN, China)
was used to express the proteins encoded-fragments inserted
in the expression vectors pET-28a. E. coli strains were cultured
in Luria–Bertani (LB) medium with kanamycin (50 µg/mL)
as needed. APP strains were cultured in Trypticase Soy Agar
(TSA) or Trypicase Soy Broth (TSB) (DIFCO Laboratories,
USA) with 10% (v/v) fetal calf serum (FBS; SIJIQING, China)
and nicotinamide adenine dinucleotide (NAD; 15 µg/mL) at
37◦C. APP L20 (serovar 5b reference strain) was purchased
from the China Institute of Veterinary Drug Control (Beijing,
China).
Bioinformatics Analysis
Signal peptide cleavage sites of open reading frames (ORFs)
were predicted using SignalP 4.1 Server1. Before the research was
carried out, the antigenicity of these antigens was calculated using
bioinformatics prediction software. To determine the antigenicity
of the six selected antigens, the complete amino acid sequences
of the proteins were predicted using the Protean program in
DNAstar; this analysis was performed based on the Jameson–
Wolf mathematical model (Figure 1). All six selected IVI antigens
proved to be highly antigenic, and the results of the prediction are
shown in Figure 1. The antigenic indices of these proteins were
more than 1.7, indicating that these IVI antigens are likely highly
antigenic.
Construction of Expression
Recombinant IVI Antigens
Gene sequences encoding IVI antigens were searched using
NCBI database. Primers for cloning these sequences were
designed using Primer Premier 5 software. The details of the
primers, sequences, and products of the IVI genes are listed in
Table 1. In the primer sequences, the underlined nucleotides
mark added restriction sites. APP L20 strain was cultured at
37◦C overnight and genome DNA was extracted using genome
extraction kit (OMEGA, USA). Using the extracted genome
1http://www.cbs.dtu.dk/services/SignalP/
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FIGURE 1 | Antigenic properties of the in vivo-induced antigens predicted using a bioinformatics approach.
TABLE 1 | Primers used to amplify and clone A. pleuropneumoniae IVI gene sequences.
Sequence name Primer Primer sequence (5′–3′) Enzyme Predicted sizes Molecular weight (kDa)
galU(0651) AP1F 5′-CGGGATCCATGAAAGTAATTATTCCGGTAGCGG-3′ BamHI 900 32.48
AP1R 5′-CCCAAGCTTATAACGTTTTAGCTAATTTTTTA-3′ HindIII
AP-galT(0994) AP2F 5′-CGGGATCCATGAGCCAACAATTTATCCTAAACG-3′ BamHI 1050 40.54
AP2R 5′-CCCAAGCTTCTATTGATTTTTATAGTGAACGCTG-3′ HindIII
AP-hflX(1962) AP3F 5′-CGGGATCCATGGAATTCCAAACGCTTGCCG-3′ BamHI 760 27.72
AP3R 5′-ACGTGTAACAGTAAGCTTGCTTCGG-3′ HindIII
APL_1166 AP4F 5′-CGGGATCCTTGAAAAAAAGTATTTACGATACCC-3′ BamHI 756 29.31
AP4R 5′-CCCAAGCTTAATTTTTTTTAACTGCCTTAATA-3′ HindIII
rnhB(0129) AP5F 5′-CGGGATCCATGAGTACAAATTTCATTTATCCTA-3′ BamHI 594 21.42
AP5R 5′-CCCAAGCTTATAAACCTAAGATTTTCTTCACC-3′ HindIII
APL_1061 AP6F 5′-CGGGATCCACGACCGCACAAGCGCAAAATAACG-3′ BamHI 597 22.19
AP6R 5′-ATAAGAATGCGGCCGCTATTTCAATCTCGTGATGTTTTTC-3′ NotI
DNA as template, genes of the six IVI antigens were amplified
using polymerase chain reaction (PCR). Each amplified gene and
vector, pET-28a were both cut by a corresponding restriction
enzyme, ligated using T4 DNA ligase (NEB, USA; Table 1) and
transformed into E. coli DH5α. Each clone was confirmed by
DNA sequencing.
Expression and Purification of the IVI
Recombinant Protein
For expression, identified recombinant plasmids were extracted
from E. coli DH5α and transformed into E. coli BL21. Clones were
cultured in LB and induced with isopropyl-β-D-thiogalactoside
(IPTG) for 4 h. Recombinant proteins were purified using
Ni-chelating affinity chromatography (BIO-RAD, USA). The
purified proteins were examined by 12% SDS-PAGE as previously
described (Figure 2).
Western Blotting
Western blotting was performed as described previously (Guo
et al., 2015). The membrane was visualized using BeyoECL Star
(BEYOTIME, China) and pictures were taken using a ChemiDoc
imaging system (BIO-RAD, USA).
Vaccination and Animal Challenge
To obtain an accurate challenge dose, the LD50 was determined
using a Reed–Muench method (Reed and Muench, 1938).
Animals were divided randomly into seven groups, 15 animals
in each group. For the initial vaccination, six groups were
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FIGURE 2 | SDS-PAGE of un-induced (A) and induced (B) recombinant strains. The expression proteins are marked with blue rectangles.
immunized subcutaneously with 50 µg rRnhB, rGalU, rGalT,
rAPL_1061, rAPL_1166, and rHflX emulsified in the same
volume of complete Freund’s adjuvant, respectively. The negative
control group was immunized with phosphate buffer solution
(PBS) emulsified in complete Freund’s adjuvant. Two weeks
following the initial immunization, the mice were given a
booster shot of the same dose of antigens and complete Freund’s
adjuvant. Before immunization and 2 weeks post-booster, blood
samples were obtained by tail bleeding. Two weeks after the
booster immunization, all groups of mice were challenged
intraperitoneally with a lethal dose of 5 × 108 colony forming
unit (CFU) (10 LD50) of App L20. The animals were intensively
monitored daily after challenge for the presence and severity of
respiratory symptoms and general illness or mortality. All the
challenged animals were euthanized; lung tissue was harvested for
histopathologic analysis.
Antibody Determination by Indirect
ELISA
IgG levels of serum from each vaccination group were
determined by indirect enzyme-linked immunosorbent assay
(ELISA) as described previously with a minor modification
(Fu et al., 2013). Briefly, the purified proteins were diluted
to an identical concentration (w/v; 2.5 µg/mL) in sodium
carbonate buffer (PH 9.6). Each well of 96-well microtiter plates
(COSTAR, USA) was coated with diluted protein (100 µL)
and incubated at 4◦C overnight. The plates were incubated
with block buffer (BEYOTIME, China) at room temperature
(RT) for 1 h then washed three times using washing buffer
(300 µL; BEYOTIME, China). Serum samples were diluted
(1:100) with primary antibody dilution buffer (BEYOTIME,
China), added to the ELISA wells and incubated overnight. The
plates were then washed three times. Horseradish peroxidase
(HRP)-labeled goat anti-mouse IgG(H+L) was diluted (1:2000)
with secondary antibody dilution buffer (BEYOTIME, China )
and added (100 µL) onto plates for incubation at RT for 1 h.
After washing three times, soluble tetramethylbenzidine (TMB)
substrate solution (TIANGEN, China) was added (100 µL), and
plates were incubated in the dark at RT for 30 min. The reaction
was terminated with 2 M H2SO4 and absorbance of each well was
read at a wavelength of 450 nm in a microplate absorbance reader
(BIO-RAD, USA).
Lymphocyte Proliferation Assay
Lymphocyte proliferation was performed with minor
modifications as previously described (Fu et al., 2013). Firstly,
spleens were isolated aseptically and processed by gentle
disruption using sterile stainless steel screen and the rubber
seal of a disposable syringe. Splenocytes were suspended in
Roswell Park Memorial Institute (RPMI) incomplete medium
(THERMO, USA). Cell suspensions were first processed using
Red Blood Cell Lysis Buffer (SOLARBIO, China) according
to manufacturer’s instructions. The erythrocyte-free cells were
washed three times with Hank’s balanced salt solution (HBSS;
THERMO, USA) and then resuspended in complete RPMI
medium (THERMO, USA). Cell counting was performed and
100 µL of cells were added (1 × 105 cells) into 96-well culture
plates (COSTAR, USA). The cells were stimulated with the
recombinant proteins (5 µg/well) or concanavalin A (ConA;
SIGMA-ALDRICH, USA) and incubated for 72 h at 37◦C in a
5% CO2 incubator. Lymphoproliferation assays were performed
using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) Cell Proliferation Assay Kit (BEYOTIME,
China), according to the manufacturer’s instructions. MTT
solution was added into each well and plates were incubated for
another 4 h. Then 100 µL formazan solutions were added to
wells and plates were incubated until formazan was dissolved
completely. The absorbance was measured at 595 nm using a
microplate absorbance reader (BIO-RAD, USA).
Analysis of the Spleen T-cell Subsets
Two weeks post-booster, aliquots of the splenocytes prepared
as mentioned above were subjected to T cells subset analysis
by flow cytometry. Briefly, cell counting was performed and
the concentration of the spleen cells was adjusted to 1 × 106
cells/mL. Hundred microliters of cell suspension was transferred
to another centrifuge tube, and stained with rat anti-mouse
CD3-Fluorescein (FITC), R-phycoerythrin/Cyanine 5 (SPRD)
(Southern Biotech, USA), rat anti-mouse CD4-R-phycoerythrin
(PE) (Southern Biotech), and rat anti-mouse CD8a-PerCP
(Southern Biotech) at 4◦C for 15 min in the dark. Stained
cells were washed in PBS and were resuspended in 450 µL
PBS. Resuspended cells were analyzed for T cell subsets by BD
fluorescence activated cell sorting (FACS) Calibur flow cytometer
(BD, USA) and the results of analysis were collected.
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FIGURE 3 | SDS-PAGE and Western blotting. (A) SDS-PAGE of six recombinant proteins. (B) The results of a western blot of six proteins reacted with
corresponding mouse anti-sera. Lane M, protein marker; lanes 1–6, RnhB, GalU, GalT, APL_1061, APL_1166, HflX.
Detection of Cytokines by ELISA
To compare the levels of Th1 and Th2 cells subsets before
vaccination and booster, cytokines (IFN-γ, IL-2, and IL-4) in
splenocyte culture supernatant were determined using an ELISA
kit (NEOBIOSCIENCE, China) per manufacturer’s instructions.
Histopathology
Lungs of animals from different groups were isolated and were
fixed by immersion in 10% neutral formalin. Immersed tissues
were sectioned at 5 µm thickness, and HE-stained for evaluation
of histopathology under an Olympus DP71 microscope.
Immunohistochemical Analysis
Immunohistochemical (IHC) method was conducted to analyze
neutrophils and macrophages infiltration in tissues from different
groups. IHC staining with monoclonal antibodies (MAbs) was
carried out on paraffin wax sections obtained from different
mouse lung sections. Two MAbs were used: rabbit anti-mouse
CD68 for macrophages and rabbit anti-mouse myeloperoxidase
(MPO) for neutrophils (Guge Biotech, Wuhan, China). Sections
were treated as described (Oh et al., 2013). The stained IHC
sections were examined in 200×magnification and taken photos.
IHC photos were analyzed by Image-Pro Plus 6.0 software.
Integrated optical density (IOD) of each photo was determined
as positive index.
Statistical Analyses
All data analyses were performed by SPSS 19.0 software
using Student’s t-test for the comparison of the differences
between different groups. P-values of < 0.05 were considered as
statistically different and were represented with asterisk. P-values
of< 0.001 were represented with two asterisks.
RESULTS
Expression of Six Recombinant Proteins
The six recombinant genes were confirmed by sequence
analysis (data not shown). The recombinant plasmids were
successfully transformed into E. coli BL21 and the respective
proteins were expressed as His-tagged fusion proteins. SDS-
PAGE confirmed that all of these fusion proteins were expressed
FIGURE 4 | Analysis of levels of IgG. Serum samples from immunized
controls and negative controls were collected before immunization and 2
weeks after booster immunization. Antibody levels were tested using an
indirect ELISA coated with the corresponding recombinant proteins. Antibody
levels were demonstrated as absorbance at 450 nm.
FIGURE 5 | Lymphocyte proliferation assay. Levels of lymphocyte
proliferation of each group were detected using an MTT method and the
results shown as absorbance at 595 nm. Splenocytes of animals 2 weeks
post-immunization were isolated and stimulated with recombinant proteins
and con A.
in E. coli BL21 with the expected molecular mass (Figure 2).
Fusion proteins were purified using Ni-chelating affinity
chromatography and determined by SDS-PAGE (Figure 3A).
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FIGURE 6 | FACS analysis. The levels of CD3+ (A), CD3+CD4+ (B), and
CD3+CD8+ (C) T-cell subsets in splenocytes from immunized groups and the
negative control group were analyzed by FACS. The average measured
percentages of CD3+, CD3+CD4+, and CD3+CD8+ T-cells with
representative scatter diagrams of the T-cells subsets detected by flow
cytometry method (data not shown). The means with standard deviations
were represented as bars graph, and are representatives of the percentages
of CD3+, CD3+CD4+, and CD3+CD8+ T-cells of spleens.
Compared with the results of SDS-PAGE for each IVI antigen
protein (Figure 3A), there was a corresponding exposure
stripe on the results of western blotting (Figure 3B). This
demonstrated that these proteins would react with corresponding
anti-sera.
Humoral Immune Responses
Two weeks after booster immunization, the serum
samples of each group were collected and the IgG
levels were tested by indirect ELISA. Referring to
FIGURE 7 | The levels of IFN-γ (A), IL-2 (B), and IL-4 (C) in cultured
spleen cells of mice injected with proteins or negative control were
determined by sandwich ELISA.
the results of indirect ELISA (Figure 4), IgG levels
of every group were increased by relatively large
margins compared with the serum before immunization.
Compared with negative group, IgG levels of each
IVI antigen protein group were significantly elevated
(P < 0.001).
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FIGURE 8 | Survival rate of mice challenged with APP strain L20 after
immunization. The animals immunized with recombinant vaccine were
challenged after 2 weeks of last booster with 5 × 108 CFU (10 LD50) of App
L20, intraperitoneally. The animals were monitored for mortality till day 14
post-challenge. Over all there was significant difference in survival of control
and vaccinated animals (P < 0.05). The figure shows the post-challenge
survival as a representative vaccine evaluation and difference in time period
between mortality of control and vaccine group.
Cell-Mediated Immune Response
Upon stimulation with recombinant proteins, except rRnhB
group, levels of lymphocyte proliferation of all the proteins in the
immune groups were higher than those of the negative control
(Figure 5). Similarly, lymphocyte proliferation of these groups
was also detected after the cells stimulated with ConA.
Distribution of CD3+, CD4+, and CD8+ T cells in the spleen
cells were evaluated by FACS. Overall trends in the proportion
of CD3+ and CD4+ T cells were higher in immunized mice
than the control group animals (Figure 6). In rGalT group, all of
CD3+, CD4+, and CD8+ showed the highest levels, which was
significantly higher than the control group (P < 0.05).
On the other hand, the levels of IFN-γ, IL-2 and IL-4
stimulated with recombinant proteins were significantly higher
in the vaccinated groups when compared with the control group
(P< 0.05; Figure 7). The levels of IL-4 in response to stimulation
with recombinant proteins were higher than the level of IFN-γ
and IL-2 (Figure 7). Except APL_1166 group, levels of IFN-γ of
six immunized groups were significantly higher than the control
(P < 0.05). With the exception of the HflX group, both levels of
IL-2 and IL-4 of five immunized groups were significantly higher
than the control group (P < 0.05).
Protective Efficiency in Murine Model
The results of vaccination and challenge experiments showed that
rGalT, rAPL_1166, and rHlfX provided 87.5, 62.5, and 62.5%
protection, respectively (Figure 8). The mortality of mice in the
negative control group was 100% after being challenged with APP
L20. The rRnhB, rGalU, and rAPL_1061 immunized groups had
an identical protection efficiency of 25% within the observation
days (Figure 8). The survival rate of mice challenged with APP
strain L20 after vaccination was shown in Figure 8.
Histopathologic Analysis
Histopathologic examination showed the infiltration of
neutrophils and macrophages in the lung tissues (Figure 9).
FIGURE 9 | Lung histopathology. Mice of each group were sacrificed
post-challenge and lungs were collected for histopathology. (A) Normal
control. (B) Negative control. (C–H) Lungs from mice immunized with RnhB,
GalU, GalT, APL_1061, APL_1166, and HflX, respectively. Hematoxylin and
Eosin (H&E), magnification 400×. (A) Normal control. (B) Negative control
mouse lung showing increased inflammatory cell infiltration in the perivascular
and peribronchial areas. (C) Tissue from mice immunized with rRnhB showing
a mild inflammatory cell infiltration in the perivascular and peribronchial areas.
(D) Lung tissue from surviving infected mouse showing significantly reduced
infiltration of inflammatory cells.
Lung tissue of mice in control group was severely damaged
and the structures of pulmonary alveoli showed pathological
changes (Figure 9B). Moreover, the lung parenchyma was
edematous (Figure 9B). However, all surviving mice from the
immunized groups did not manifest significant pathological
damage (Figure 9). Immunized groups had only moderate
inflammation with infiltration of mixed mononuclear cells and
neutrophils (Figures 9C–H).
Immunohistochemical Analysis
Compared with IHC analysis results of normal control,
IOD of neutrophils and macrophages in negative control
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FIGURE 10 | Immunohistochemical analysis. Mice of each group were sacrificed post-challenge and lungs were collected for histopathology. (A)
Immunohistochemical (IHC) analysis for macrophages. (B) IHC analysis for neutrophils. (a) Normal control. (b) Negative control. (c–h) Lungs from mice immunized
with RnhB, GalU, GalT, APL_1061, APL_1166, and HflX, respectively. (i) Statistical analysis of inflammatory cells.
group were significant higher than normal group (P < 0.05;
Figures 10A,B). IOD of neutrophils in all immunized groups
except GalU were not significantly different to that of the
normal group. Nevertheless, neither IOD of negative control nor
all immunized groups were significantly different with normal
control (Figure 10B).
DISCUSSION
Actinobacillus pleuropneumoniae is one of the most important
bacterial pathogens, which causes PCP (Li et al., 2016). For
strategies aimed at controlling this disease, vaccines appear
to be the most effective choice. Over the last several years,
numerous studies have been performed with the goal of
generating APP vaccines with improved protective efficacy
rates. Inactivated whole-cell vaccines have been the standard
means used to control PCP. These “traditional” vaccines
have reduced, to some extent, mortality rates, but have
shown little use in curbing morbidity rates. There was no
cross-protection for hosts immunized with inactivated vaccine
(Jolie et al., 1995). However, attenuated mutant vaccine
candidates have been shown to provide a partial cross-
protection and reduced morbidity (Tonpitak et al., 2002;
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Maas et al., 2006). So far, DNA vaccines (Chiang et al., 2009;
Lu et al., 2011), subunit vaccines (Sjolund and Wallgren, 2010;
Lopez-Bermudez et al., 2014), recombinant subunit vaccines
(Jirawattanapong et al., 2008; Oldfield et al., 2008, 2009; Shao
et al., 2010; Sadilkova et al., 2012; Seo et al., 2013; Park et al.,
2015; Li et al., 2016), ghost vaccine (Katinger et al., 1999; Hensel
et al., 2000), and live vector vaccine (Shin et al., 2013; Hur and
Lee, 2014) for APP had been studied.
The current APP vaccines derive primarily from apx, omp
and other key antigens, all of which are known virulence
factors of APP; these vaccines so far have shown to provide
partial protection. However, the current battery of APP vaccines
does not protect against all APP pathogenic serovars. We have
previously applied IVIAT to screen the genome of APP L20 and
a number of IVI antigens were identified (Zhang et al., 2015).
Compared with in vitro conditions, the levels of transcription
of these antigens in vivo were up-regulated. Furthermore,
these antigens were demonstrated to be conserved in different
serovars. We hypothesized that the IVI antigens identified in our
previous study were highly antigenic and could provide immune
protection against APP. Among these antigens, APL_1061
and APL_1166 are APP antigens of unknown function. RnhB
(Itaya, 1990) and HflX (John et al., 2005) are ribonuclease H
and GTP-binding protein, respectively. GalU, UTP-α-D-glucose-
1-phosphate uridylyltransferase is involved in the LPS core
biosynthesis (Rioux et al., 1999), and GalU and GalT are enzymes
involved in metabolism of galactose (Ebrecht et al., 2015), all
essential for the virulence of different bacterial pathogens (Chai
et al., 2012; Caboni et al., 2015).
We performed the vaccine trial using these antigens. Our
studies indicated that IVI antigens conferred a partial protection
in a mouse challenge model. Vaccinated groups showed high
level antibody responses. Also, increased level of cytokines was
detected in our vaccinated groups. Among these antigens, GalT,
APL_1166, and HflX immunized groups showed relatively high
levels of immune protection and could be considered as potential
vaccine candidates for further study in piglets.
This is the first report to determine whether the IVI antigens
could induce an immune response against App challenge in a
mouse model. Both humoral and cellular immune responses
were induced in the immunized animals using these IVI antigens
as vaccine candidates. However, our recombinant IVI proteins
could elicit a strong Th2 response. In conclusion, our results
showed that IVI proteins can be used as protective antigens
against APP in mice and should be considered as promising
vaccine candidates for further studies in a piglet model.
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